Prakt. lékáren. 2011; 7(1): 7-11

Niacin-laropiprant combination: novel approach not only to treatment of dyslipidemia

MUDr.Michal Vrablík, Ph.D., MUDr.Eva Motyková, prof.MUDr.Richard Češka, CSc.

Centrum preventivní kardiologie, 3. interní klinika 1. LF UK a VFN, Praha

Complex management of dyslipidemia provides a chance of further reduction of atherosclerotic vascular complications beyond current

therapeutic options. A nicotinic acid (niacin) offers a substantial modification of triglyceride and HDL-cholesterol levels together

with beneficial impact on LDL-cholesterol and Lp (a) concentrations. Interacting with GPR109A receptors on the surface of hepatocytes,

adipocytes and other tissues, niacin induces numerous metabolic changes, thus, explaining its desirable as well as harmful effects. Niacin

administration mostly in combination with a statin was associated with a significant slowing of progression or even regression of

atherosclerosis in clinical trials. Major limitation of niacin widespread use- its side effects- can be partly overcome by thorough education

of patients. Modern pharmacological forms of extended-release niacin, and particularly, its combination with a prostaglandin D2

receptor antagonist – laropiprant- can enhance its use in everyday practice.

Keywords: niacin, cardiovascular disease, dyslipidemia, HDL-c, Lp (a), laropiprant

Published: February 1, 2011  Show citation